|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 144.2 DKK | -3.58% |
|
-1.77% | -18.77% |
| Mar. 13 | Swiss Regulator Clears Bavarian Nordic’s Jynneos for Smallpox Immunization in Adults | MT |
| Mar. 13 | Bavarian Nordic A/S Receives Approval of Smallpox and Mpox Vaccine in Switzerland | CI |
Bavarian Nordic A/S maintained earnings guidance for the year 2022. For the year, the company expects revenues to be between DKK 2,800 million to DKK 3,000 million.
| 1st Jan change | Capi. | |
|---|---|---|
| -18.77% | 1.61B | |
| +24.17% | 556B | |
| -6.33% | 354B | |
| +19.90% | 331B | |
| +7.95% | 296B | |
| +13.45% | 233B | |
| +6.04% | 201B | |
| -10.51% | 193B | |
| -12.26% | 143B | |
| -6.47% | 144B |
BAVARIAN NORDIC A/S 
